Physiomics plc (AIM: PYC) is an Oxford based mathematical modelling and data science consultancy enabling smarter development of oncology drugs.

Using modelling and simulation techniques, we support our clients to derive insights from available data to answer critical R&D questions, enable better informed study design, support regulatory submissions and articulate the value of their asset, from discovery to the clinic.

We bring decades of experience across quantitative pharmacology, data science and systems biology to deliver high quality bespoke solutions for our clients across a range of therapeutic modalities, including ADCs. Our team utilise a variety of modelling techniques depending on the question at hand, from empirical to semi-mechanistic PK/PD and QSP models. These tools can be used to inform steps such as;

Discovery: Target ID and lead candidate selection, MOA Hypothesis

Preclinical: In vivo study design and analysis, IND/CTA support, Ph1 dose definition, clinical study design

Clinical: Population modelling, dose & schedule optimisation for efficacy/safety (mono and combination therapies), dose adjustment for patient population/indications

General: Data Gap Analysis, Data science support

Testimonials:

• “Physiomics has helped us achieve a more quantitative and translational understanding of our novel molecules…. We have found the group to be talented, experienced, and committed to delivering high quality results in a timely manner. ”​, SVP Preclinical Development, Bicycle Therapeutics.
• “Working with Physiomics we were able to​ integrate multi-level preclinical data to build confidence on the clinical potential of our​ molecule ... providing insight and working with great​ transparency, flexibility, and communication.”, Head of Translational Pharmacometrics, Servier.

www.physiomics.co.uk